Skip to main content
Erschienen in: Journal of Gastrointestinal Surgery 7/2015

01.07.2015 | Original Article

Lymph Node Harvest During Esophagectomy Is Not Influenced by Use of Neoadjuvant Therapy or Clinical Disease Stage

verfasst von: Renato A. Luna, James P. Dolan, Brian S. Diggs, Nathan W. Bronson, Brett C. Sheppard, Paul H. Schipper, Brandon H. Tieu, Benjamin T. Feeney, Ken M. Gatter, Gina M. Vaccaro, Charles R. Thomas Jr., John G. Hunter

Erschienen in: Journal of Gastrointestinal Surgery | Ausgabe 7/2015

Einloggen, um Zugang zu erhalten

Abstract

Introduction

The purpose of this study was to evaluate the effects of neoadjuvant therapy on lymph node harvest (LNH), lymph node ratio (LNR), and overall survival rates after esophagectomy.

Methods

A retrospective analysis of 111 patients who underwent esophagectomy for esophageal adenocarcinoma from 2001 to 2010 was performed. Patients were divided into two groups: neoadjuvant chemoradiotherapy prior to surgery (NEOSURG) versus surgery alone (SURG).

Results

There were 83 patients (75 %) in the NEOSURG group and 28 (25 %) in the SURG group with a mean age of 66 and 67 years, respectively. The median LNH in the NEOSURG group and SURG group was 16.0 and 15.5, respectively (p = 0.57). Within the NEOSURG group, the median LNH was 16 for complete responders, 14 for partial responders, 16 for nonresponders, and 18 in those who were pathologically upstaged (p = 0.434). The median LNR was 0, 0, 0.1, and 0.2, respectively (p < 0.001). Complete response after neoadjuvant therapy demonstrated a trend toward improved survival (p = 0.056).

Conclusion

The LNH was not significantly influenced by neoadjuvant treatment or pathologic response. The LNR was inversely related to pathologic response after neoadjuvant therapy. Complete pathologic response to neoadjuvant therapy trends to improve survival rates.
Literatur
1.
Zurück zum Zitat Twine CP, Lewis WG, Morgan MA, Chan D, Clark GW, Havard T, Crosby TD, Roberts SA, Williams GT. The assessment of prognosis of surgically resected oesophageal cancer is dependent on the number of lymph nodes examined pathologically. Histopathology 2009;55:46–52.PubMedCrossRef Twine CP, Lewis WG, Morgan MA, Chan D, Clark GW, Havard T, Crosby TD, Roberts SA, Williams GT. The assessment of prognosis of surgically resected oesophageal cancer is dependent on the number of lymph nodes examined pathologically. Histopathology 2009;55:46–52.PubMedCrossRef
2.
Zurück zum Zitat Peyre CG, Hagen JA, DeMeester SR, Altorki NK, Ancona E, Griffin SM, Hölscher A, Lerut T, Law S, Rice TW, Ruol A, van Lanschot JJ, Wong J, DeMeester TR. The number of lymph nodes removed predicts survival in esophageal cancer: an international study on the impact of extent of surgical resection. Ann Surg 2008;248:549–56.PubMedCrossRef Peyre CG, Hagen JA, DeMeester SR, Altorki NK, Ancona E, Griffin SM, Hölscher A, Lerut T, Law S, Rice TW, Ruol A, van Lanschot JJ, Wong J, DeMeester TR. The number of lymph nodes removed predicts survival in esophageal cancer: an international study on the impact of extent of surgical resection. Ann Surg 2008;248:549–56.PubMedCrossRef
3.
Zurück zum Zitat Yang HX, Xu Y, Fu JH, Wang JY, Lin P, Rong TH. An evaluation of the number of lymph nodes examined and survival for node-negative esophageal carcinoma: data from China. Ann Surg Oncol 2010;17:1901–11.PubMedCrossRef Yang HX, Xu Y, Fu JH, Wang JY, Lin P, Rong TH. An evaluation of the number of lymph nodes examined and survival for node-negative esophageal carcinoma: data from China. Ann Surg Oncol 2010;17:1901–11.PubMedCrossRef
4.
Zurück zum Zitat Altorki NK, Zhou XK, Stiles B, Port JL, Paul S, Lee PC, Mazumdar M. Total number of resected lymph nodes predicts survival in esophageal cancer. Ann Surg 2008;248:221–6.PubMedCrossRef Altorki NK, Zhou XK, Stiles B, Port JL, Paul S, Lee PC, Mazumdar M. Total number of resected lymph nodes predicts survival in esophageal cancer. Ann Surg 2008;248:221–6.PubMedCrossRef
5.
Zurück zum Zitat Mariette C, Piessen G, Briez N, Triboulet JP. The number of metastatic lymph nodes and the ratio between metastatic and examined lymph nodes are independent prognostic factors in esophageal cancer regardless of Neoadjuvant chemoradiation or lymphadenectomy extent. Ann Surg 2008;247:365–71.PubMedCrossRef Mariette C, Piessen G, Briez N, Triboulet JP. The number of metastatic lymph nodes and the ratio between metastatic and examined lymph nodes are independent prognostic factors in esophageal cancer regardless of Neoadjuvant chemoradiation or lymphadenectomy extent. Ann Surg 2008;247:365–71.PubMedCrossRef
6.
Zurück zum Zitat Lewis I. The surgical treatment of carcinoma of the oesophagus; with special reference to a new operation for growths of the middle third. Br J Surg 1946;34:18–31.PubMedCrossRef Lewis I. The surgical treatment of carcinoma of the oesophagus; with special reference to a new operation for growths of the middle third. Br J Surg 1946;34:18–31.PubMedCrossRef
7.
Zurück zum Zitat de Steur WO, Dikken JL, Hartgrink HH. Lymph node dissection in resectable advanced gastric cancer. Dig Surg. 2013;30:96–103.PubMedCrossRef de Steur WO, Dikken JL, Hartgrink HH. Lymph node dissection in resectable advanced gastric cancer. Dig Surg. 2013;30:96–103.PubMedCrossRef
8.
Zurück zum Zitat Hoppo T, Jobe BA, Hunter JG. Minimally invasive esophagectomy: the evolution and technique of minimally invasive surgery for esophageal cancer. World J Surg 2011;35:1454–63.PubMedCrossRef Hoppo T, Jobe BA, Hunter JG. Minimally invasive esophagectomy: the evolution and technique of minimally invasive surgery for esophageal cancer. World J Surg 2011;35:1454–63.PubMedCrossRef
9.
Zurück zum Zitat Orringer MB, Marshall B, Iannettoni MD. Eliminating the cervical esophagogastric anastomotic leak with a side-to-side stapled anastomosis. J Thorac Cardiovasc Surg 2000;119:277–88.PubMedCrossRef Orringer MB, Marshall B, Iannettoni MD. Eliminating the cervical esophagogastric anastomotic leak with a side-to-side stapled anastomosis. J Thorac Cardiovasc Surg 2000;119:277–88.PubMedCrossRef
10.
Zurück zum Zitat Rice TW, Blackston EH, Rusch VW. 7th Edition of the AJCC Cancer Staging Manual: Esophagus and Esophagogastric Junction. Ann Surg Oncol 2010;17:1721–1724.PubMedCrossRef Rice TW, Blackston EH, Rusch VW. 7th Edition of the AJCC Cancer Staging Manual: Esophagus and Esophagogastric Junction. Ann Surg Oncol 2010;17:1721–1724.PubMedCrossRef
11.
Zurück zum Zitat Groth SS, Virnig BA, Whitson BA, DeFor TE, Li ZZ, Tuttle TM, Maddaus MA. Determination of the minimum number of lymph nodes to examine to maximize survival in patients with esophageal carcinoma: data from the Surveillance Epidemiology and End Results. J Thorac Cardiovasc Surg 2010;139:612–620.PubMedCrossRef Groth SS, Virnig BA, Whitson BA, DeFor TE, Li ZZ, Tuttle TM, Maddaus MA. Determination of the minimum number of lymph nodes to examine to maximize survival in patients with esophageal carcinoma: data from the Surveillance Epidemiology and End Results. J Thorac Cardiovasc Surg 2010;139:612–620.PubMedCrossRef
12.
Zurück zum Zitat Bollschweiler E, Besch S, Drebber U, Schröder W, Mönig SP, Vallböhmer D, Baldus SE, Metzger R, Hölscher AH. Influence of Neoadjuvant chemoradiation on the number and size of analyzed lymph nodes in esophageal cancer. Ann Surg Oncol 2010;17:3187–94.PubMedCrossRef Bollschweiler E, Besch S, Drebber U, Schröder W, Mönig SP, Vallböhmer D, Baldus SE, Metzger R, Hölscher AH. Influence of Neoadjuvant chemoradiation on the number and size of analyzed lymph nodes in esophageal cancer. Ann Surg Oncol 2010;17:3187–94.PubMedCrossRef
13.
Zurück zum Zitat Merkow RP, Bilimoria KY, McCarter MD, Chow WB, Ko CY, Bentrem DJ. Use of Multimodality Neoadjuvant Therapy for Esophageal Cancer in the United States: Assessment of 987 Hospitals. Ann Surg Oncol 2012;19:357–64.PubMedCrossRef Merkow RP, Bilimoria KY, McCarter MD, Chow WB, Ko CY, Bentrem DJ. Use of Multimodality Neoadjuvant Therapy for Esophageal Cancer in the United States: Assessment of 987 Hospitals. Ann Surg Oncol 2012;19:357–64.PubMedCrossRef
14.
Zurück zum Zitat Sjoquist KM, Burmeister BH, Smithers BM, Zalcberg JR, Simes RJ, Barbour A, Gebski V. Australasian Gastro-Intestinal Trials Group. Survival after Neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol 2011;12:681–92.PubMedCrossRef Sjoquist KM, Burmeister BH, Smithers BM, Zalcberg JR, Simes RJ, Barbour A, Gebski V. Australasian Gastro-Intestinal Trials Group. Survival after Neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol 2011;12:681–92.PubMedCrossRef
15.
Zurück zum Zitat Aiko S, Yoshizumi Y, Ishizuka T, Sakano T, Kumano I, Sugiura Y, Maehara T. Reduction rate of lymph node metastasis as a significant prognostic factor in esophageal cancer patients treated with neoadjuvant chemoradiation therapy. Dis Esophagus 2007;20:94–101.PubMedCrossRef Aiko S, Yoshizumi Y, Ishizuka T, Sakano T, Kumano I, Sugiura Y, Maehara T. Reduction rate of lymph node metastasis as a significant prognostic factor in esophageal cancer patients treated with neoadjuvant chemoradiation therapy. Dis Esophagus 2007;20:94–101.PubMedCrossRef
16.
Zurück zum Zitat Orditura M, Galizia G, Morgillo F, Martinelli E, Lieto E, Vitiello F, DiMartino N, Pacelli R, Renda A, Ciardiello F, DeVita F. Complete response to preoperative chemoradiation and survival in esophageal cancer: a pooled analysis of three single-institutions phase II trials. Dis Esophagus 2012;25:130–6.PubMedCrossRef Orditura M, Galizia G, Morgillo F, Martinelli E, Lieto E, Vitiello F, DiMartino N, Pacelli R, Renda A, Ciardiello F, DeVita F. Complete response to preoperative chemoradiation and survival in esophageal cancer: a pooled analysis of three single-institutions phase II trials. Dis Esophagus 2012;25:130–6.PubMedCrossRef
17.
Zurück zum Zitat Stiles BM, Christos P, Port JL, Lee PC, Paul S, Saunders J, Altorki NK. Predictors of survival in patients with persistent nodal metastases after preoperative chemotherapy for esophageal cancer. J Thorac Cardiovasc Surg 2010;139:387–94.PubMedCrossRef Stiles BM, Christos P, Port JL, Lee PC, Paul S, Saunders J, Altorki NK. Predictors of survival in patients with persistent nodal metastases after preoperative chemotherapy for esophageal cancer. J Thorac Cardiovasc Surg 2010;139:387–94.PubMedCrossRef
18.
Zurück zum Zitat Saha AK, Sutton C, Rotimi O, Dexter S, Sue-Ling H, Sarela AI. Neoadjuvant chemotherapy and surgery for esophageal adenocarcinoma: prognostic value of circumferential resection margin and stratification of N1 category. Ann Surg Oncol 2009;16:1364–70.PubMedCrossRef Saha AK, Sutton C, Rotimi O, Dexter S, Sue-Ling H, Sarela AI. Neoadjuvant chemotherapy and surgery for esophageal adenocarcinoma: prognostic value of circumferential resection margin and stratification of N1 category. Ann Surg Oncol 2009;16:1364–70.PubMedCrossRef
19.
Zurück zum Zitat Le Prise E, Etienne PL, Meunier B, Maddern G, Ben Hassel M, Gedouin D, Boutin D, Campion JP, Launois B. A randomized study of chemotherapy, radiation therapy, and surgery versus surgery for localized squamous cell carcinoma of the esophagus. Cancer 1994;73:1779–84.PubMedCrossRef Le Prise E, Etienne PL, Meunier B, Maddern G, Ben Hassel M, Gedouin D, Boutin D, Campion JP, Launois B. A randomized study of chemotherapy, radiation therapy, and surgery versus surgery for localized squamous cell carcinoma of the esophagus. Cancer 1994;73:1779–84.PubMedCrossRef
20.
Zurück zum Zitat Tepper J, Krasna MJ, Niedzwiecki D, Hollis D, Reed CE, Goldberg R, Kiel K, Willett C, Sugarbaker D, Mayer R. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol 2008;26:1086–92.PubMedCrossRef Tepper J, Krasna MJ, Niedzwiecki D, Hollis D, Reed CE, Goldberg R, Kiel K, Willett C, Sugarbaker D, Mayer R. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol 2008;26:1086–92.PubMedCrossRef
21.
Zurück zum Zitat Dolan JP, Kaur T, Diggs BS, Luna RA, Sheppard BC, Schipper PH, Tieu BH, Bakis G, Vaccaro GM, Holland JM, Gatter KM, Conroy MA, Thomas CA Jr, Hunter JG. Significant understaging is seen in clinically staged T2N0 esophageal cancer patients undergoing esophagectomy. Dis Esophagus. 2015 Feb 24. doi: 10.1111/dote.12334. Dolan JP, Kaur T, Diggs BS, Luna RA, Sheppard BC, Schipper PH, Tieu BH, Bakis G, Vaccaro GM, Holland JM, Gatter KM, Conroy MA, Thomas CA Jr, Hunter JG. Significant understaging is seen in clinically staged T2N0 esophageal cancer patients undergoing esophagectomy. Dis Esophagus. 2015 Feb 24. doi: 10.1111/dote.12334.
22.
Zurück zum Zitat Stiles BM, Mirza F, Coppolino A, Port JL, Lee PC, Paul S, Altorki NK. Clinical T2-T3N0M0 esophageal cancer: the risk of node positive disease. Ann Thorac Surg 2011;92:491–6; discussion 496–8.PubMedCrossRef Stiles BM, Mirza F, Coppolino A, Port JL, Lee PC, Paul S, Altorki NK. Clinical T2-T3N0M0 esophageal cancer: the risk of node positive disease. Ann Thorac Surg 2011;92:491–6; discussion 496–8.PubMedCrossRef
23.
Zurück zum Zitat Chen WH, Chao YK, Chang HK, Tseng CK, Wu YC, Liu YH, Hsieh MJ, Liu HP. Long-term outcomes following Neoadjuvant chemoradiotherapy in patients with clinical T2N0 esophageal squamous cell carcinoma. Dis Esophagus 2012;25:250–5.PubMedCrossRef Chen WH, Chao YK, Chang HK, Tseng CK, Wu YC, Liu YH, Hsieh MJ, Liu HP. Long-term outcomes following Neoadjuvant chemoradiotherapy in patients with clinical T2N0 esophageal squamous cell carcinoma. Dis Esophagus 2012;25:250–5.PubMedCrossRef
24.
Zurück zum Zitat Rice TW, Mason DP, Murthy SC, Zuccaro G Jr, Adelstein DJ, Rybicki LA, Blackstone EHJ. T2N0M0 esophageal cancer. Thorac Cardiovasc Surg 2007;133:317–24.CrossRef Rice TW, Mason DP, Murthy SC, Zuccaro G Jr, Adelstein DJ, Rybicki LA, Blackstone EHJ. T2N0M0 esophageal cancer. Thorac Cardiovasc Surg 2007;133:317–24.CrossRef
Metadaten
Titel
Lymph Node Harvest During Esophagectomy Is Not Influenced by Use of Neoadjuvant Therapy or Clinical Disease Stage
verfasst von
Renato A. Luna
James P. Dolan
Brian S. Diggs
Nathan W. Bronson
Brett C. Sheppard
Paul H. Schipper
Brandon H. Tieu
Benjamin T. Feeney
Ken M. Gatter
Gina M. Vaccaro
Charles R. Thomas Jr.
John G. Hunter
Publikationsdatum
01.07.2015
Verlag
Springer US
Erschienen in
Journal of Gastrointestinal Surgery / Ausgabe 7/2015
Print ISSN: 1091-255X
Elektronische ISSN: 1873-4626
DOI
https://doi.org/10.1007/s11605-015-2821-4

Weitere Artikel der Ausgabe 7/2015

Journal of Gastrointestinal Surgery 7/2015 Zur Ausgabe

Evidence-Based Current Surgical Practice

Clostridium Difficile Infection from a Surgical Perspective

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

CME: 2 Punkte

Prof. Dr. med. Gregor Antoniadis Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

CME: 2 Punkte

Dr. med. Benjamin Meyknecht, PD Dr. med. Oliver Pieske Das Webinar S2e-Leitlinie „Distale Radiusfraktur“ beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

CME: 2 Punkte

Dr. med. Mihailo Andric
Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.